Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: Correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings

Neurology

Volumn 47, Issue 6, 1996, Pages 1535-1541

  Trojano, M ^a   Avolio, C ^a   Simone, I L ^a   Defazio, G ^a   Manzari, C ^a   De Robertis, F ^a   Calo A ^a   Livrea, P ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GADOLINIUM PENTETATE; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISABILITY; DISEASE ACTIVITY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; SCORING SYSTEM; SERUM;

EID: 0029758280     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1535     Document Type: Article

References (41)

1. Raine CS. Demyelinating diseases. In: Davis RL, Robertson DM, eds. Textbook of neuropathology. 2nd ed. Baltimore: Williams & Wilkins, 1991:535-620.
2. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990;136:1309-1316.
3. Washington R, Burton J, Todd RF III, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994;35:89-97.
4. Raine CS, Lee SC, Scheinberg LC, Duijvestijn AM, Cross AH. Adhesion molecule on endothelial cells in the central nervous system: an emerging area in the neuroimmunology of multiple sclerosis. Clin Immunol Immunopathol 1990;57:173-187.
5. Wilcox CE, Ward AMV, Evans A, Baker D, Rothlein R, Turk JL. Endothelial cell expression of the intercellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1990;30:43-51.
6. Pober JS, Gimbrone MA, Lapierre LA, et al. Overlapping patterns of activation of human endothelial cells by interleukin-1, tumor necrosis factor and immune interferon. J Immunol 1986;137:1893-1896.
7. Fabry Z, Waldschmidt MN, Hendrickson D, et al. Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55. J Neuroimmunol 1992;36:1-11.
8. Wong D, Dorovini-Zis K. Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide. J Neuroimmunol 1992;39:11-22.
9. Hawkins CP, Munro PMG, Landon DN, McDonald WI. Metabolically dependent blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis. Acta Neuropathol 1992;83:630-635.
10. Cannella B, Cross AH, Raine CS. Adhesion-related molecules in the central nervous system: upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab Invest 1991;1:23-31.
11. Cannella B, Cross AH, Raine CS. Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis. J Neuroimmunol 1993;46:43-56.
12. Archelos JJ, Jung S, Maurer M, et al. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 1993;34: 145-154.
13. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. Ann Neurol 1993;33:646-649.
14. Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis: correlations with TNF-alpha and blood-brain barrier damage. J Neuroimmunol 1993;43:15-21.
15. Hartung HP, Michels M, Reiners K, Seeldrayers P, Archelos JJ, Toyka KV. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 1993;43:2331-2335.
16. Rieckmann P, Martin S, Weichselbraun I, et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 1994;44:2367-2372.
17. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993;43:2679-2682.
18. Rieckmann P, Nünke K, Burchhardt M, et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol 1993;47:133-140.
19. Jander S, Heidenreich F, Stoll G. Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases. Neurology 1993;43:1809-1813.
20. Dore-Duffy P, Newman W, Balabanov R, et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 1995;37:55-62.
21. Leeuwenberg JF, Smeets EF, Neefjes JJ, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-549.
22. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991;147: 3788-3793.
23. Vollmer T, Dalton J, Klotz K, Goldstein J. Astrocyte-lymphocyte binding: the role of immune cytokines and ICAM-1. Neurology 1992;42(suppl 3):158-159.
24. Cannella B, Cross AH, Raine CS. Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system. J Exp Med 1990;172:162-170.
25. Rieckmann P, Michel U, Albrecht M, Bruck W, Wockel L, Felgenhauer K. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 1995;60:9-15.
26. Hawkins CP, Munro PMG, Mackenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990;113:365-378.
27. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or correlation in 37 cases at biopsy and three cases at autopsy. Neuroradiology 1991;180:467-474.
28. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocol. Ann Neurol 1983;13:227-231.
29. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-568.
30. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995;58:300-306.
31. Confavreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:671-676.
32. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
33. Andersson M, Alvarez-Cermeno J, Bernardi G, et al. Clinical neurochemistry for diagnosis in multiple sclerosis: European consensus. J Neurol Neurosurg Psychiatry 1994;54:99-108.
34. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. Part I. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-390.
35. Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 1987;163:319-328.
36. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. Part III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977;37:397-401.
37. Barkhof F, Frequin STFM, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing-remitting multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992; 42:63-67.
38. Barkhof F, Tas MW, Frequin STFM, et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994;36:382-387.
39. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology 1995;45:1122-1126.
40. Bakker DA, Ludwin SK. Blood-brain barrier permeability during cuprizone-induced demyelination: implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci 1987;78:125-137.
41. van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990;144:4579-4586.